Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

PURPOSE: This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. A unicenter translational substudy assessed potential mechanisms of lurbinectedin resistance. PATIENTS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz, Cristina, Llop-Guevara, Alba, Garber, Judy E., Arun, Banu K., Pérez Fidalgo, José A., Lluch, Ana, Telli, Melinda L., Fernández, Cristian, Kahatt, Carmen, Galmarini, Carlos M., Soto-Matos, Arturo, Alfaro, Vicente, Pérez de la Haza, Aitor, Domchek, Susan M., Antolin, Silvia, Vahdat, Linda, Tung, Nadine M., Lopez, Rafael, Arribas, Joaquín, Vivancos, Ana, Baselga, José, Serra, Violeta, Balmaña, Judith, Isakoff, Steven J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209089/
https://www.ncbi.nlm.nih.gov/pubmed/30240327
http://dx.doi.org/10.1200/JCO.2018.78.6558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209089/
https://www.ncbi.nlm.nih.gov/pubmed/30240327
http://dx.doi.org/10.1200/JCO.2018.78.6558

Ejemplares similares